Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AnalizaDx Solvent Interaction Technology (SIA) technology combined with the Nanosphere Verisens ultra-sensitive PSA assay (research use only) demonstrated positive results for improved prostate cancer diagnosis, according to Case Western Reserve University School of Medicine - Case Medical Center principal investigator Mark Stovsky.
Subscribe to our email newsletter
Verisens PSA is an in-vitro diagnostic assay for the high-sensitivity detection and quantification of prostate specific antigen (PSA), developed in collaboration with the International Institute for Nanotechnology at Northwestern University.
SIA is a technology with the potential to discover and screen for structural changes in circulating proteins in serum and other biological fluids.
Nanosphere is collaborating with AnalizaDx, which has developed a proprietary platform to screen for protein biomarkers in serum and other biological fluids, for development of PSA tests for prostate cancer.
The data presented for blood serum showed that at a sensitivity of 100%, the specificity was 76%, with a negative predictive value of 100% (ruling out patients who do not have prostate cancer) and a positive predictive value of 84% (likelihood that a patient ruled in would have cancer based on biopsy).
Thus, the use of the Nanosphere Verisens ultra-sensitive PSA assay achieved sensitivity and specificity required for prostate cancer diagnosis, that is not possible with existing commercial assays.